Cytokine Release Syndrome (CRS) is an acute systemic inflammatory syndrome, which is characterized by fever and multiple organ dysfunction that is associated with chimeric antigen receptor (CAR)-T cell therapy, therapeutic antibodies, and haploidentical allogeneic transplantation.
Even though cytokines act to direct immune response, the higher levels of cytokines with increased inflammation can be harmful as they interfere with several body functions. In severe cases, CRS can cause organ failure in heart, lung, kidney, liver, and brain function that may even lead to death.
The main cytokines implicated in the pathogenesis of CRS include interleukin-6 (IL-6), IL-10, tumour necrosis factor (TNF), IL-1, IL-2, IL-8, interferon (IFN)-γ, monocyte chemoattractant protein 1 (MCP-1) and granulocyte-macrophage colony-stimulating factor (GM-CSF) and others. CRS clinically manifests when large numbers of lymphocytes (B cells, T cells, and/or natural killer cells) and/or myeloid cells (macrophages, dendritic cells, and monocytes) become activated and release inflammatory cytokines.
Cytokine Release Syndrome Epidemiological Segmentation
The Epidemiological Segmentation of Cytokine Release Syndrome in 7MM from 2017 to 2030 is segmented as:-
- Total Number of B-cell NHL Patients receiving CAR T-Cell Therapies
- Total Number of Acute lymphoblastic leukaemia (ALL) Patients receiving CAR-T Cell Therapies
- Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies
- Total Number of Patients developing Cytokine Release Syndrome (CRS) following CART therapies
- Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade
Cytokine Release Syndrome Epidemiology
- Total number of Hematologic patients receiving CAR-T cell therapies in the United States in 2017 was 41
- Cytokine Release Syndrome cases in the United States in 2017 were 31
The market size of Cytokine Release Syndrome (CRS) in the 7MM in 2017 was USD 0.16 million
Cytokine Release Syndrome Market Drivers
- Increasing incidence of Acute cytokine release syndrome (CRS)
- Increasing R&D activities
- Non-competitive landscape
Cytokine Release Syndrome Market Barriers
- Lack of awareness about the disease
- Lack of disease understanding
- Misdiagnosis of CRS
Cytokine Release Syndrome Emerging Drugs
The emerging drugs of the Cytokine Release Syndrome market are
- Canakinumab (Ilaris)
- Defitelio (Defibrotide)
And many others.
Cytokine Release Syndrome Key Players
The key players in the Cytokine Release Syndrome market are
- Novartis Pharmaceuticals
- Incyte Corporation
- Jazz pharmaceuticals
- Swedish Orphan Biovitrum (Sobi)
And many others.